ALLO Allogene Therapeutics, Inc.

Overview and Growth

Allogene Therapeutics, Inc. generated $0.00 of revenue in fiscal 2025, with net loss of $190.89M and an operating cash outflow of $149.25M. Revenue was 100.0% below fiscal 2024 revenue of $22.00K, marking a top-line contraction. The company reported diluted EPS of -$0.87, adding a shareholder-level measure to the absolute income figures considered below. Diluted shares averaged 220.62M; this is the reported share base over which the company’s diluted per-share earnings were spread. Diluted shares moved 13.2% from 194.81M in fiscal 2024, leaving the current share base higher year over year. The company employed $415.90M of total assets, the balance-sheet base supporting its current operating and cash-flow results.

Profitability

Operations produced a $209.31M operating loss before non-operating and tax effects. The bottom-line result was a net loss of $190.89M after operating, financing, tax, and other recognized items. The company reported negative EBITDA of $196.96M, adding a pre-interest, tax, depreciation, and amortization view of the operating shortfall. The pretax result was a loss of $190.89M, establishing the deficit before tax effects. The reported income-tax provision was $0.00, the amount recognized between pretax income and the final net-income result. The net loss equaled 65.3% of period-end equity, showing the deficit relative to book capital. The net loss equaled 45.9% of period-end assets, showing the deficit relative to the asset base. Compared with a $257.59M net loss in fiscal 2024, the current loss improved to $190.89M.

Liquidity and Capital Structure

The company held $415.90M of assets against $123.36M of liabilities and $292.54M of equity, revealing how the asset base was financed. Current assets were $257.75M against $32.51M of current liabilities, framing the resources and obligations classified within the near-term balance-sheet horizon. The current ratio was 7.93x, with current assets exceeding current liabilities and providing a short-term liquidity cushion. The company held $51.69M in cash and equivalents, a narrower liquidity measure than total current assets. The cash balance equaled 159.0% of current liabilities, showing how much near-term coverage came from cash alone. Equity equaled 70.3% of assets, showing the shareholder-capital layer within the company’s balance sheet. The liabilities-to-assets relationship was 29.7%, placing reported obligations against the full positive asset balance. Cash and equivalents equaled 12.4% of total assets, showing the liquid cash component within the company’s broader resource base. Compared with $548.71M in fiscal 2024, the current asset base moved 24.2% and finished lower. Reported equity changed 30.7% from $422.18M in fiscal 2024, placing the current capital base lower year over year. The reported cash balance changed 31.3% from $75.22M in fiscal 2024, ending lower year over year.

Cash Flow and Earnings Quality

Cash flow from operations was an outflow of $149.25M, showing that operations absorbed cash during the period. Capital spending of $386.00K added to the period’s operating cash use, reinforcing the overall cash deficit after investment for the year. Negative free cash flow was $149.63M, leaving a cash deficit after capital spending and reducing financial flexibility. The cash deficit after capital spending represented 36.0% of the period-end asset base. Compared with a $200.30M operating cash outflow in fiscal 2024, the current outflow improved to $149.25M.

Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated Oct 21, 2026.